Fertility and reproductive technology use in testicular cancer survivors in Japan: A multi-institutional, cross-sectional study.
EORTC QLQ-TC26
cross-sectional study
fertility
survivor
testicular cancer
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
02
03
2021
accepted:
23
06
2021
pubmed:
20
7
2021
medline:
16
10
2021
entrez:
19
7
2021
Statut:
ppublish
Résumé
To evaluate fertility and use of reproductive technology of testicular cancer survivors in a multi-institutional, cross-sectional study. This study recruited testicular cancer survivors who were followed after treatment for testicular cancer at eight high-volume institutions between 2018 and 2019. The participants completed the questionnaires on marital status, fertility and use of reproductive technology. A total of 567 testicular cancer survivors, with a median age of 43 years, responded to the questionnaire. Chemotherapy was given to 398 survivors, including three cycles of cisplatin-based chemotherapy in 106 patients and four cycles in 147 patients. Among 153 survivors who attempted sperm cryopreservation, 133 (87%) could preserve sperm. Of the 28 survivors whose cryopreserved sperm was used, 17 (61%) fathered children. Of the 72 survivors who fathered children without the use of cryopreserved sperm, 59 (82%) fathered naturally. Whereas 33 (20%) of 169 survivors treated without chemotherapy fathered children without using cryopreserved sperm, 39 (10%) of 398 treated with chemotherapy fathered children (P < 0.05). Furthermore, the paternity rate was 12% and 5% in testicular cancer survivors with three and four cycles of cisplatin-based chemotherapy, respectively (P < 0.05). However, of 121 survivors who wanted to have children, 14 (12%) received counseling about infertility treatment. Testicular cancer survivors preserving their sperm have a higher paternity rate after chemotherapy, especially after four cycles, than those not using cryopreserved sperm. Physicians who give chemotherapy for testicular cancer need to take particular care not only with respect to recurrence of testicular cancer, but also to post-treatment fertility.
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1047-1052Subventions
Organisme : Grants-in-Aidfor Scientific Research from the Japan Society for the Promotion of Science
ID : 18K09185
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Japanese Urological Association.
Références
Trabert B, Chen J, Devesa SS, Bray F, McGlynn KA. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. Andrology. 2015; 3: 4-12.
Miki T, Kamoi K, Fujimoto H et al. Clinical characteristics and oncological outcomes of testicular cancer patients registered in 2005 and 2008: the first large-scale study from the Cancer Registration Committee of the Japanese Urological Association. Int. J. Urol. 2014; 21: S1-6.
Shintaku I, Satoh M, Okajima E et al. Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan. Jpn J. Clin. Oncol. 2008; 38: 281-7.
Kojima T, Kawai K, Tsuchiya K et al. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor. Int. J. Urol. 2015; 22: 923-7.
Yamashita S, Koyama J, Goto T et al. Trends in age and histology of testicular cancer from 1980-2019: a single-center study. Tohoku J. Exp. Med. 2020; 252: 219-24.
International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. 1997; 15: 594-603.
Stephenson A, Eggener SE, Bass EB et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J. Urol. 2019; 202: 272-81.
Albers P, Albrecht W, Algaba F et al. Guidelines on testicular cancer: 2015 update. Eur. Urol. 2015; 68: 1054-68.
Brydøy M, Fosså SD, Klepp O et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur. Urol. 2010; 58: 134-40.
Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J. Clin. Oncol. 2010; 28: 4831-41.
Lee SJ, Schover LR, Partridge AH et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol. 2006; 24: 2917-31.
Oktay K, Harvey BE, Partridge AH et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J. Clin. Oncol. 2018; 36: 1994-2001.
Oncology JSoC. JSCO clincal practice guidelines 2017 for fertility preservation in childhood, adolescent and young adult cancer patients. Kanehara, Japan, 2017.
Kawai K, Nishiyama H. Preservation of fertility of adult male cancer patients treated with chemotherapy. Int. J. Clin. Oncol. 2019; 24: 34-40.
Holzner B, Efficace F, Basso U et al. Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26. Qual. Life Res. 2013; 22: 369-78.
Bager L, Elsbernd A, Nissen A, Daugaard G, Pappot H. Danish translation and pilot testing of the European Organization for Research and Treatment of Cancer QLQ-TC 26 (EORTC QLQ-TC26) questionnaire to assess health-related quality of life in patients with testicular cancer. Health Qual. Life Outcomes 2018; 16: 128.
Arai Y, Yamashita S, Fujii S et al. Linguistic validation of japanese version of european organization for research and treatment of cancer quality of life questionnaire-testicular cancer 26 (eortc qlq-tc26). Jpn J. Urol. 2017; 108: 128-36.
Yamashita S, Suzukamo Y, Kakimoto K et al. Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer. Int. J. Urol. 2021; 28: 176-82.
Yamashita S, Kakimoto K, Uemura M et al. Health-related quality of life in testicular cancer survivors in Japan: a multi-institutional, cross-sectional study using the EORTC QLQ-TC26. Urology 2021; https://doi.org/10.1016/j.urology.2021.02.039.
Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-92.
Brydøy M, Fosså SD, Klepp O et al. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. Br. J. Cancer 2012; 107: 1833-9.
Pont J, Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. Fertil. Steril. 1997; 68: 1-5.
Weibring K, Nord C, Ståhl O et al. Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment. Ann. Oncol. 2019; 30: 604-11.
Spermon JR, Kiemeney LA, Meuleman EJ, Ramos L, Wetzels AM, Witjes JA. Fertility in men with testicular germ cell tumors. Fertil. Steril. 2003; 79(Suppl 3): 1543-9.
Sonnenburg DW, Brames MJ, Case-Eads S, Einhorn LH. Utilization of sperm banking and barriers to its use in testicular cancer patients. Support. Care Cancer 2015; 23: 2763-8.
Magelssen H, Haugen TB, von During V, Melve KK, Sandstad B, Fossa SD. Twenty years experience with semen cryopreservation in testicular cancer patients: who needs it? Eur. Urol. 2005; 48: 779-85.
Žáková J, Lousová E, Ventruba P et al. Sperm cryopreservation before testicular cancer treatment and its subsequent utilization for the treatment of infertility. Sci. World J. 2014; 2014: 1-5.
Ucar MA, Arikan F, Coskun HS, Kondak Y, Tatli AM, Goksu SS. Fertility in testicular cancer patients: a single-centre study in Turkey. Int. J. Clin. Oncol. 2020; 25: 495-500.
Stoehr B, Schachtner L, Pichler R et al. Influence of achieved paternity on quality of life in testicular cancer survivors. BJU Int. 2013; 111: E207-12.
Arai Y, Kawakita M, Okada Y, Yoshida O. Sexuality and fertility in long-term survivors of testicular cancer. J. Clin. Oncol. 1997; 15: 1444-8.
Katanoda K, Shibata A, Matsuda T et al. Childhood, adolescent and young adult cancer incidence in Japan in 2009-2011. Jpn J. Clin. Oncol. 2017; 47: 762-71.
Jorgensen N, Rajpert-De Meyts E, Main KM, Skakkebaek NE. Testicular dysgenesis syndrome comprises some but not all cases of hypospadias and impaired spermatogenesis. Int. J. Androl. 2010; 33: 298-303.